
Opinion|Videos|December 8, 2025
Concluding Thoughts: Practical Tips, Resources, and More
Author(s)Jonathan M. Meyer, MD, DLFAPA
Summarizing key messages and reinforce the value of TDM in improving patient outcomes.
Advertisement
This video covers the following questions:
- If you could leave psychiatrists with 3 key takeaways about clozapine TDM, what would they be?
- How do you envision the role of TDM evolving as we move toward more personalized and precision-based psychiatry?
- Any final advice for clinicians looking to optimize clozapine treatment through better use of monitoring tools and data?
Advertisement
Related to this article

Bessel van der Kolk, MD, argues that trauma is rooted in attachment and that psychedelic-assisted therapy may help where medications have not.

Emestedastat did not significantly slow disease progression, but a prespecified analysis showed a higher rate of zero CDR-SB progression.

In this CME article, explore the clinical evidence and ethical reasoning to guide use of long-acting injectable antipsychotics in patient care.

In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.

2R,6R-HNK reproduces ketamine’s rapid antidepressant profile in rodents without dissociation or abuse signals, and is now in four phase 2 trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Why Depression Subtypes Matter: Lessons From 25 Years in the Clinic
2
Ketamine for Treatment-Resistant Depression: Practical Clinical Considerations
3
The New Ketamine Metabolite: A Conversation With Carlos Zarate, MD; Todd Gould, MD; and Craig J. Thomas, PhD
4
DT-120 in Anxiety and Depression: Phase 3 Efficacy and Safety Findings
5




